Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Renflexis | infliximab | rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tremfya | guselkumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Orfadin | nitisinone | Hereditary tyrosinemia type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adcetris | Brentuximab Vedotin | HL at high risk of relapse or progression post-ASCT | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | Venetoclax | Chronic Lymphocytic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | For locally advanced or metastatic urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Bavencio | Avelumab | metastatic Merkel Cell Carcinoma (mMCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vemlidy | tenofovir alafenamide | Hepatitis B, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Actemra | tocilizumab | Giant cell arteritis (GCA) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vectibix | Panitumumab | Left Sided Metastatic Colorectal Cancer (mCRC) | Do not reimburse | Complete |
Last Updated : April 28, 2024